Skip to main navigation Skip to search Skip to main content

Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results from the Randomized, Phase II DESTINY-Lung02 Trial

  • Koichi Goto
  • , Yasushi Goto
  • , Toshio Kubo
  • , Kiichiro Ninomiya
  • , Sang We Kim
  • , David Planchard
  • , Myung Ju Ahn
  • , Egbert F. Smit
  • , Adrianus Johannes De Langen
  • , Maurice Pérol
  • , Elvire Pons-Tostivint
  • , Silvia Novello
  • , Hidetoshi Hayashi
  • , Junichi Shimizu
  • , Dong Wan Kim
  • , Chih Hsi Kuo
  • , James Chih Hsin Yang
  • , Kaline Pereira
  • , Fu Chih Cheng
  • , Ayumi Taguchi
  • Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Jänne
  • National Cancer Center Japan
  • Okayama University
  • University of Ulsan
  • Gustave Roussy
  • Leiden University
  • Netherlands Cancer Institute
  • Centre Léon Bérard
  • Nantes University
  • Azienda Ospedaliera S. Luigi Gonzaga
  • Kindai University
  • Aichi Cancer Center Hospital and Research Institute
  • Seoul National University
  • Chang Gung University
  • National Taiwan University
  • Daiichi Sankyo Company, Limited
  • Dana-Farber Cancer Institute

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results from the Randomized, Phase II DESTINY-Lung02 Trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science